Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2
Withdrawn
- Conditions
- Lymphoma, Large B-Cell, DiffusePrimary Mediastinal Large B-cell LymphomaTransformed Indolent Lymphoma
- Interventions
- Biological: MDV9300
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Medivation, Inc.
- Registration Number
- NCT02653989
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT01435369
- Locations
- 🇺🇸
Moffitt Cancer Center Cutaneous Oncology Department, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Ruttenberg Cancer Clinic - The Mount Sinai Hospital, New York, New York, United States
An Extension of the CONCERT Protocol (DIM18)
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 672
- Registration Number
- NCT01152216
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 362
- Registration Number
- NCT01085266
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease
Phase 3
Terminated
- Conditions
- Moderate to Severe Alzheimer
- Interventions
- Drug: Dimebon (latrepirdine)Drug: Placebo
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT00954590
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT00920946
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT00890305
- Locations
- 🇺🇸
The Cancer Center of Huntsville, PC, Huntsville, Alabama, United States
🇧🇬InterDistrict Dispensary of Oncology Diseases with Stationary, Varna, Bulgaria
🇧🇬InterDistrict Dispensary in Oncology Diseases with Stationary, Shumen, Bulgaria
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 1003
- Registration Number
- NCT00829374
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00829816
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00704782
- Locations
- 🇺🇸
Xenoscience, Inc., Phoenix, Arizona, United States
🇺🇸Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Sun Health Research Institute, Sun City, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath